Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer

BACKGROUND: In patients with advanced non-small cell lung cancer (aNSCLC), cemiplimab plus chemotherapy prolonged overall survival (OS) and progression-free survival (PFS) significantly compared to chemotherapy alone. The cost-effectiveness of these drugs is still uncertain. The aim of this study is...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Xueyan, Chen, Xiaoyu, Li, Huijuan, Li, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171429/
https://www.ncbi.nlm.nih.gov/pubmed/37182130
http://dx.doi.org/10.3389/fonc.2023.1113374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171429/
https://www.ncbi.nlm.nih.gov/pubmed/37182130
http://dx.doi.org/10.3389/fonc.2023.1113374

Ejemplares similares